Helping The others Realize The Advantages Of Antidepressant agent 5
MI-CP151 was a stage 1b randomised, double-blind, placebo controlled, dose-escalation, multicentre review To judge a number of intravenous doses of sifalimumab, in Grownup people with dermatomyositis or polymyositis (NCT00533091). Main demo targets were to evaluate the safety and tolerability of sifalimumab in dermatomyositis or polymyositis people